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Introduction
The Bcl-2 family comprises two broad categories of pro-survival (Bcl-2, Bcl-X L , Bcl-w, Mcl-1, and A1) and pro-apoptotic (Bax, Bak, Bim, Bid, Puma, Bad, Noxa, Bik, Bmf, and Hrk) proteins (1) (2) (3) (4) . In general, the balance between these proteins determines whether a cell lives or dies. The overexpression of pro-survival Bcl-2 family members provides one means by which cancer cells can overcome the continual assault of cellular stresses that would cause normal cells to undergo apoptosis. Their overexpression has also been shown to correlate with poor prognosis and resistance to therapy (5) . For example, overexpression of Bcl-2 has been shown to confer resistance to cytotoxic agents in lung cancer (6, 7) , while both Bcl-2 and Bcl-X L are associated with the emergence of androgen independence and chemoresistance in prostate cancer (8) (9) (10) (11) . Thus, directly targeting the apoptotic machinery represents an attractive strategy for enhancing the efficacy of certain chemotherapeutics (12) .
Recently, we described the discovery of ABT-263 (navitoclax), an orally bioavailable Bcl-2 family protein inhibitor with high affinity (<1 nmol/L) to Bcl-2, Bcl-X L , and Bclw, but not Mcl-1 or A1 (13) . Navitoclax exhibits potent single agent antitumor activity in multiple murine xenograft models of small cell lung cancer (SCLC), leukemia, and lymphoma (13, 14) and, in addition, potentiates the activity of clinically relevant chemotherapeutic regimens -e.g., rituximab, rapamycin, R-CHOP, and bortezomib, in several models of hematologic malignancies (14, 15) . However, the interrogation of the ability of navitoclax to enhance the activity of chemotherapeutic agents in solid tumors has been limited (16) .. These cell lines are commercially available and often utilized for drug development.
Navitoclax enhanced the activity of several chemotherapeutic agents, representing diverse mechanisms of action, across a broad spectrum of tumor types. To extend these observations, potent combinations were tested in murine xenograft models. Navitoclax demonstrated activity in combination with erlotinib or docetaxel in lung or ovarian cancer models in vitro and in vivo. Subsequent mechanism of action and siRNA-mediated knockdown experiments indicated that this efficacy was associated with the neutralization of Mcl-1. Taken together, our studies provide a mechanistic rationale for the use of navitoclax in combination with standard-of-care agents that neutralize Mcl-1 or increase pro-apoptotic BH3 proteins such as Bim and Noxa.
Materials and Methods

Compounds and cell lines
Chemotherapeutic agents were purchased from Sigma (St. Louis, MO) Mikroorganismen und Zellkulturen GmbH). These cell lines were not reauthenticated before using in this study. They are grown in medium conditions recommended by the suppliers or in RPMI medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA).
Cell viability assays
5,000 cells were plated per well in a 96-well plate and incubated with each therapeutic agent ± 1 μM navitoclax for 72 hr in a total volume of 100 μl culture medium supplemented with 10% fetal bovine serum. Cytotoxicity was assessed using the CellTiter-Glo Assay that measures the ATP content of the cells according to manufacturer's specifications (Promega, Madison, WI). Agents that induced ≥ 20% reduction in combination with navitoclax below what was observed with agent alone across two doses were considered synergistic hits from the screen. To quantitatively assess the combination effects of navitoclax with other chemotherapeutic agents, experiments were performed to determine the combination index (CI), which is a value derived from the multiple drug-effect equation of Chou-Talalay (17) . CalcuSyn software from Biosoft (Cambridge, UK) was used for this analysis. Briefly, this method of analysis distinguishes between synergistic, additive, and antagonistic drug-drug interactions. A CI value = 1.0 indicates an additive effect. CI values < 1.0 reflect a synergistic effect, while CI values > 1.0 reflect an antagonistic effect. Mitochondrial cytochrome c release assay SKOV3 cells were pretreated with 1.5 nM docetaxel or 2.5 μM gemcitabine for 48 hr, washed and resuspended in cell permeability buffer (20 mM HEPES, pH 7.2, 100 mM KCl, 5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 250 mM sucrose, 0.015% digitonin, Complete Protease Inhibitor; Roche), and incubated on ice for 3-5 min. Permeabilized cells were then incubated with 10 μM navitoclax, enantiomer, Bim-BH3 peptide or vehicle at 30ºC for 75 minutes. Mitochondrial and cytosolic fractions were separated by centrifugation at 16000 x g at 4ºC for 10 minutes, resolved on a 10% SDS-PAGE gel and analyzed by immunoblotting using a mouse anti-cytochrome c antibody (BD Biosciences, San Jose, CA).
High content analysis
A standard immunofluorescence protocol was used to prepare samples for high content analysis. SKOV3 cells were propagated in RPMI-1640 supplemented with 10% FBS.
Cells were plated at a density of 2,000 cells per well (100 µL) in 96-well Collagen Icoated microplates (BD Biosciences, San Jose, CA) and incubated overnight under standard cell culture conditions. On the next day, cells were treated with docetaxel or vehicle by addition of a 50 μl solution containing a 3x compound stock and incubated for an additional 48 hr. Cells were then challenged with navitoclax for the indicated times. %PR, %CR and %ORR are defined as previously described (14) . All studies utilized 8-10 mice per group. Statistical comparisons of tumor growth rate and tumor growth delay utilized the Wilcoxon rank sum test and the Mantel-Cox log rank test, respectively. Navitoclax was formulated in 10% ethanol, 30% PEG 400, and 60% Phosal 50 PG and administered orally by gavage. Docetaxel was purchased from Sanofi Aventis (Paris, France), and gemcitabine was purchased from Eli Lilly (Indianapolis, IN). These agents were dosed intravenously and intraperitoneally, respectively, at the schedule and dose described in the table descriptions. Erlotinib was formulated in 7.5% Captisol (sulfobutylether-β-cyclodextran) and dosed daily by oral gavage. 
Results
Navitoclax potentiates multiple therapeutic agents across multiple tumor types
The single agent cellular activity of navitoclax has only been shown in SCLC and hematological malignancies (13, 18) (Table 1) .
Navitoclax enhances the activity of docetaxel in vivo
As shown in Figure 1B clinically relevant anti-microtubule agent approved for use in a variety of tumors (19) . To extend these observations to in vivo, navitoclax was tested in combination with docetaxel in the SKOV3 ovarian cancer xenograft model using a variety of different schedules ( Figure 2 ). As a monotherapy, navitoclax dosed orally once a day at 100 mg/kg/day for 2, 14 or 21 days was not efficacious in the SKOV3 xenograft model (Figure 2 ). Docetaxel administered once weekly for 3 cycles at 10 mg/kg/day produced a significant decrease in tumor burden (TGI) of 82% with a delay in regrowth (TGD) of 114% ( Table   2 ). In contrast, bolus dosing of docetaxel dosed 30 mg/kg once i.v. inhibited tumor growth by only 48% with no significant effect on time-to-progression. Overall response rates were slightly higher when cyclical dosing was administered, rather than bolus dosing (30% v. 0%). Table 2 ). Effects on delay of tumor regrowth and overall response with concurrent, chronically dosed navitoclax were significantly improved in both docetaxel regimens compared to docetaxel alone. Tumor growth delay (TGD), a measurement of durability of antitumor effect, was also significantly improved from 12% to 135% and from 114% to >175% in the bolus dosing and cyclical dosing, respectively. Overall response rates were also significantly improved from 0% to 89% and 30% to 100% in the bolus dosing and cyclical dosing, respectively. Concurrent, acute dosing of navitoclax (2d) with bolus administration of docetaxel also yielded greater than additive results, with tumor growth inhibition from 57 to 86% and tumor growth delay from 12% to 54% ( Figure 2C , Table   2 ). Sequential dosing of docetaxel and navitoclax was also investigated. Administration of docetaxel on day 1, followed by 14 days of navitoclax therapy induced a significant inhibition in tumor growth and a greater than additive delay in regrowth, similar to acute concurrent administration of navitoclax and docetaxel ( Figure 2D 
Navitoclax enhances the activity of erlotinib in vitro
In addition to the broad synergy observed with cytotoxic agents, navitoclax also enhanced the activity of erlotinib, an epidermal growth factor receptor (EGFR)-specific kinase inhibitor. Positive combination activity between navitoclax and erlotinib was 
Navitoclax enhances the activity of erlotinib in vivo
To confirm the synergistic effects of navitoclax and erlotinib on tumor cell proliferation observed in vitro in the NCI-H1650 model, we tested the combination of these two targeted agents in vivo. As a single agent 100 mg/kg navitoclax alone dosed daily had no significant anti-tumor activity, while daily dosing of erlotinib at 50 mg/kg resulted in significant tumor stasis (%TGI = 52) during a 21 day treatment period (Figure 4C) . Figure 4C ). The latter was sustained for 25 days even after the cessation of dosing ( Figure 4C ). Additionally the combination of navitoclax and erlotinib was well tolerated, resulting in less than 5% body weight loss during the treatment period.
To investigate potential mechanisms of action underlying the enhanced combination activity of navitoclax and erlotinib in the NCI-H1650 xenograft model in vivo, tumors were harvested post-treatment and analyzed for EGFR and Bcl-2 pathway markers.
Treatment with erlotinib resulted in decreased pERK levels and induced significant down-modulation of Mcl-1 and up-regulation of Bim ( Figure 4D ), which is consistent with previous in vitro findings ( Figure 4B ). Thus, the enhanced anti-tumor activity of erlotinib in combination with navitoclax in vivo is due to simultaneous inhibition of the EGFR and Bcl-2 pro-survival pathways. 
Discussion
Defects in the apoptotic cascade are a hallmark of cancer and are often associated with chemoresistance (29) . Thus, agents that restore the ability of cancer cells to undergo apoptosis may enhance the activity of chemotherapies when used in combination. We recently reported the discovery of navitoclax, an orally bioavailable small molecule Bcl-2 family protein inhibitor currently in Phase 1/2 clinical development. Preclinically, navitoclax exhibits single-agent activity in small cell lung cancer and leukemia and lymphoma cell lines but has limited activity in the majority of solid tumor cell lines examined (13) (14) (15) 30) . In combination, navitoclax has been shown to enhance the efficacy of rapamycin, rituximab, R-CHOP and bortezomib in various leukemia and lymphoma models (13, 15) . In non-small cell lung cancer xenograft tumor models, navitoclax enhances the efficacy of taxanes (16) improved overall response rates compared to docetaxel treatment alone. Additionally, combination treatment resulted in more durable anti-tumor responses, as evidenced by the significant increase of %TGD. In that it has been noted that the scheduling of docetaxel dosing can have a significant effect on antitumor activity (16, 31), we investigated a variety of doses and schedules in our combination studies. Addition of navitoclax to docetaxel treatment resulted in enhanced efficacy under a variety of dose schedules. We find that navitoclax is effective when administered concurrent with or immediately after dosing of docetaxel, while pre-dosing with navitoclax prior to docetaxel administration did not significantly enhance efficacy. The combinations of navitoclax-docetaxel and navitoclax-gemcitabine were evaluated once in N87 (gastric) and OVCAR5 (ovarian) xenograft models (Supplemental Figure 1) . Consistent with our in vitro findings, these combinations demonstrated enhanced anti-tumor activity in vivo over that of the chemotherapeutic treatment alone, as evidenced by a significant increase in %ORR (from 50% to 100%) for navitoclax-docetaxel in N87 and significant improvement in %TDG (from 39% to 76%) for navitoclax-gemcitabine in OVCAR-5 (Supplemental Table 1 ).
Mechanistically, we observed that navitoclax induces cytochrome c release and caspase- Table 2 e: P < 0.05 v. 
